New study published in Cell Metabolism reveals that a specific gut bacterium, Streptomyces aureofaciens (S. aureofaciens) Tü117, may contribute to high blood pressure (hypertension)—and targeting it could offer a novel therapeutic approach!
🚀 Key Findings from the Study:
🔹 Gut Microbe-Driven Hypertension: High-salt diets (HSD) increase S. aureofaciens Tü117, leading to elevated α-lipomycin, a bacterial metabolite linked to impaired vasodilation and higher blood pressure (BP).
🔹 Mechanism Behind It: α-lipomycin disrupts blood vessel relaxation via the TRPV4 pathway, leading to hypertension.
🔹 A Probiotic Solution? 🥛💊: Lactobacillus plantarum (L. plantarum) CCFM639, a probiotic strain, was found to lower BP in mice by inhibiting the growth of S. aureofaciens Tü117.
🔹 Human Relevance: A pilot study showed that L. plantarum supplementation reduced BP in individuals with pre-hypertension or early-stage hypertension—without medication!
🔬 Why It Matters?
✅ First-of-its-kind evidence linking gut microbiota to hypertension through α-lipomycin.
✅ Potential for probiotic therapy as a natural, gut-based intervention for BP management.
✅ New directions for hypertension treatment beyond traditional medications.
📖 Read the full study in Cell Metabolism: 🔗 Link
💬 Could gut-targeted therapies be the future of blood pressure control? Share your thoughts below! ⬇️
